ArticleDiscover oncology2025
Bibliometric analysis and recent trends on tyrosine kinase inhibitors in leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeukemia treatment has been revolutionized by tyrosine kinase inhibitors (TKIs), but comprehensive understanding of the global research landscape remains fragmented. This study aims to provide a systematic bibliometric analysis of TKIs research in leukemia to identify research trends, collaboration patterns, and emerging hotspots.
methodsThis bibliometric analysis using the Web of Science Core Collection database to identify relevant publications about TKIs in leukemia between January 1, 2000 and March 17, 2025. Visualization and trend analyses were performed using VOSviewer, CiteSpace, and the R package "bibliometrix".
resultsA total of 3,238 eligible publications were retrieved, authored by 16,992 individuals across 567 institutions and 100 countries. The USA led in total publications (830) and citations (69,620). The University of Texas System (articles = 624) and University of Texas MD Anderson Cancer Center (articles = 587) emerged as major contributors. Blood (articles = 227), Leukemia (articles = 130), and Leukemia & Lymphoma (articles = 134) were the top publishing journals. Keyword co-occurrence analysis identified six distinct clusters: Molecular Mechanisms, Clinical Management, Clinical Treatment Approaches, Disease-Specific Targets, Clinical Trials and Patient Outcomes, and Treatment Response Assessment.
conclusionThis bibliometric study reveals the dynamic evolution of TKIs research in leukemia research over the past 25 years. The findings highlight key contributors, collaboration patterns, and thematic transitions from molecular targeting to functional cure strategies. These insights offer a valuable foundation for strategic planning, translational research, and global collaboration in the field of hematologic oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.